Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.44 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.44 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.44 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.44 |
| ▸ | AOC2 | O75106 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7797805 | 0.82 | FFAR1 (0.51) | TAAR1FFAR1SLC5A1SLC5A2KMT2A | |
| SCHEMBL16416582 | 0.82 | ESR1 (0.50) | TAAR1FFAR1SLC5A1SLC5A2HPGD | |
| SCHEMBL4662624 | 0.82 | TAAR1 (0.46) | TAAR1FFAR1AOC3SLC5A1SLC5A2 | |
| SCHEMBL3139297 | 0.81 | TAAR1 (0.52) | TAAR1FFAR1KMT2APOLB | |
| SCHEMBL11132861 | 0.81 | RAB9A (0.51) | FFAR1AOC3KMT2APOLBPLAAT3 | |
| SCHEMBL9242991 | 0.81 | GFER (0.48) | FFAR1KMT2AMAOAMAOB | |
| SCHEMBL4435477 | 0.80 | RIPK1 (0.43) | FFAR1KMT2AMAOAMAOB | |
| SCHEMBL28448148 | 0.80 | FFAR1 (0.50) | TAAR1FFAR1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL14958586 | 0.80 | MEN1 (0.47) | TAAR1FFAR1AOC3SLC5A1SLC5A2 | |
| SCHEMBL14959151 | 0.80 | TDP1 (0.62) | TAAR1KMT2APOLBAPEX1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119331033-A | Catalyst CudppfBH4And its use in catalyzing the reduction of alpha, beta-unsaturated amides | 安徽大学 | 2025-01-21 | — | — | CN | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-8946302-B2 | Selective sigma-1 receptor ligands | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-02-03 | — | — | US | disclosed |
| US-8445473-B2 | Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130102571-A1 | SELECTIVE SIGMA-1 RECEPTOR LIGANDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-04-25 | — | — | US | disclosed |
| US-8349898-B2 | Sigma-1 receptor ligands and methods of use | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-20100179111-A1 | SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE | WARF - WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | TAAR1 190/4885FFAR1 118/4885AOC3 3180/4885 |
| US-20100179111-A1 | SIGMA-1 RECEPTOR LIGANDS AND METHODS OF USE | SIGMAR1, OPRL1, OPRK1 | TAAR1 12/4885FFAR1 38/4885AOC3 1617/4885 |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | TAAR1 2134/4885FFAR1 4734/4885AOC3 1191/4885 |
| US-20130102571-A1 | SELECTIVE SIGMA-1 RECEPTOR LIGANDS | SIGMAR1, OPRL1, OPRK1 | TAAR1 15/4885FFAR1 54/4885AOC3 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.